Form 4: Teladoc Health Director Sandra Fenwick Granted 28,986 Restricted Stock Units

Teladoc Health, Inc. Director Sandra L. Fenwick was granted 28,986 restricted stock units on May 22, 2025, as reported in a recent SEC Form 4 filing.

Summary

• Sandra L. Fenwick, a Director of Teladoc Health, Inc. (TDOC), acquired 28,986 Restricted Stock Units (RSUs) on May 22, 2025.
• Each RSU represents a contingent right to receive one share of TDOC common stock.
• The RSUs were acquired at a price of $0, which is typical for equity grants as a form of compensation.
• Following this transaction, Ms. Fenwick beneficially owns 28,986 Restricted Stock Units directly.
• The RSUs are scheduled to vest in full on the earlier of May 22, 2026, or the day immediately preceding Teladoc's 2026 annual meeting of stockholders.
• Vested shares will be delivered to Ms. Fenwick upon separation of service, a change of control, or her death, as per the company's Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 7

Explanation: The grant of equity compensation to a director is a positive signal of alignment with long-term shareholder interests and is a standard practice. It does not indicate any immediate financial distress or exceptional positive news, but rather a routine and generally favorable corporate governance action.

Positives

• The grant of restricted stock units aligns the director's interests with long-term shareholder value, as the value of the units is tied to the company's stock performance.
• Equity compensation for directors is a common practice that helps attract and retain experienced board members.

Negatives

• No direct negative financial implications are apparent from this specific RSU grant, as it is a standard form of non-cash compensation.

Risks

• The value of the restricted stock units is subject to the future performance of Teladoc Health's common stock, meaning the actual value realized by the director could be lower than the grant date value if the stock price declines.
• Vesting conditions tie the director's full ownership to continued service or specific corporate events, introducing a forfeiture risk if conditions are not met.

Future Outlook

This filing does not provide a general future outlook for Teladoc Health, Inc. It specifically details a future vesting schedule for the granted restricted stock units, which will occur on the earlier of May 22, 2026, or the day preceding the 2026 annual meeting of stockholders.

Industry Context

The grant of restricted stock units to a non-employee director is a common practice across various industries, including healthcare technology, to align director incentives with long-term shareholder interests and retain experienced board members. This specific transaction reflects standard corporate governance practices for director compensation within the industry.

Comparison to Industry Standards

• The grant of restricted stock units as a form of compensation for non-employee directors is a widely accepted industry standard across publicly traded companies, including those in the healthcare technology sector like Teladoc Health.
• While the specific number of units (28,986) and vesting schedule (full vesting by May 2026 or 2026 annual meeting) are specific to Teladoc's compensation plan, the mechanism itself is comparable to practices at companies such as Amwell (AMWL) or other digital health providers, which often use equity grants to incentivize and retain board members.
• The $0 acquisition price is standard for such grants, representing compensation rather than a purchase.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns their interests with shareholders, as the value of the compensation is tied to the company's stock performance. It represents a non-cash compensation expense for the company.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The restricted stock units are expected to vest on the earlier of May 22, 2026, or the day immediately preceding Teladoc Health's 2026 annual meeting of stockholders.
• Vested shares will be delivered to the reporting person upon separation of service, a change of control, or death, as per the company's deferred compensation plan.

Key Dates

Recommendation

Keywords

Teladoc Health, TDOC, Restricted Stock Units, RSU, Insider Trading, Form 4, Equity Compensation, Director Compensation, Stock Grant, Beneficial Ownership